ModeX at OPKO: Do the Partnerships Fund the Pipeline or Just Delay New Capital?

After the main article framed OPKO as leaner at the core but still burdened by expensive capital, this follow-up isolates the partnership axis around ModeX and the adjacent peptide pipeline. The question here is not whether OPKO has external validation. It does. BARDA, Merck, Regeneron, and Entera all provide that. The real question is more economic: does the money coming in under those agreements already fund the pace of pipeline advancement, or does it mostly allow OPKO to run more programs before the capital question moves back to the front of the story.

It is easy to bundle BARDA, Merck, Regeneron, and Entera into one headline and call it “external funding.” That is the wrong read. BARDA pays for work performed under a cost-plus-fee structure, with revenue recognized only against actual costs incurred. Regeneron paid about $7 million upfront, but pushed most of the economic value into selected molecules, milestones, and future royalties. Merck reimburses and supports a relatively narrow EBV program. Entera sits closer to the obligation side than the funding side, because OPKO bought 3,685,226 Entera shares at $2.17 per share, about $8 million in total, so Entera could fund its 40% share through the end of Phase 1 in the oral OXM program.

The second paradox sits directly in the income statement. In 2025, research and development expense rose to $121.9 million from $103.0 million. The company explicitly ties that increase to higher manufacturing expense for biological products, including costs under BARDA, and to higher employee-related expense due to an increase in headcount, primarily at ModeX. At the same time, the line that directly offsets R&D, grants and funding from collaboration agreements, fell to only $3.1 million from $11.9 million in 2024. So the outside validation is real, but in 2025 it did not translate into funding coverage that kept pace with the rising cost base.

The third point is that the breadth of the pipeline itself makes full “coverage” difficult. Within ModeX, OPKO is advancing MDX2001, which had already reached the fifth dose level, MDX2004, which had already dosed a first patient, and MDX2003, which is expected to enter a first-in-human study in early 2026. At the same time, BARDA is funding infectious-disease antibody work, Merck is tied to the EBV vaccine, and Entera now sits alongside oral OXM, oral LA-PTH, and oral GLP-2. So the issue is not whether the company has enough partnership headlines. The issue is which parts of the pipeline are genuinely externally funded, and which parts still sit on OPKO’s own budget.

Four conclusions follow immediately:

• BARDA is the only agreement that currently looks like a relatively clear ongoing funding engine: $28.5 million was recognized in 2025, and $49.9 million of remaining performance obligations are expected to be recognized through February 2028.
• Regeneron is probably the most impressive outside validation at the headline level, but economically it is still mostly an option today: a relatively small upfront payment now, with the real value pushed into selected molecules and downstream development.
• Merck provides real support, but narrower support than the headline suggests. The company says Merck reimbursements are the primary component of the R&D offset line, yet that offset weakened materially in 2025.
• Entera is not “incoming funding” in the ordinary sense. It is a risk-sharing structure, with cash leaving OPKO today to keep the partner in the program through Phase 1, and with the possibility that OPKO will have to carry the program alone later if Entera does not continue.

Four Partnerships, Four Different Economic Models

BARDA: This is the line that comes closest to true pipeline funding in the classic sense. Revenue is recognized against work performed, so it funds real execution rather than distant optionality. That is also why BARDA appears on both sides of the story. It shows up once as $28.5 million of 2025 revenue and again as one of the reasons biological manufacturing expense moved higher. It is a real contract, but a narrow and disciplined one. In December 2025, the contract value was cut from $110.0 million to $103.5 million after mRNA-related activities were de-scoped, and the overall potential value fell from $205.0 million to $198.5 million. BARDA also conducts periodic progress assessments and retains discretion to terminate. So even the clearest funding layer has already been trimmed.

Regeneron: This is where the gap between headline and current economics is the widest. The agreement sounds large, and it is. OPKO disclosed more than $200 million per selected molecule, more than $1.0 billion of potential value if multiple products advance, and tiered global net sales royalties up to the low double digits at the highest tier. But the hard current money is just the $7.0 million upfront payment. The key value here is not the upfront. It is the fact that Regeneron will fund and lead any preclinical, clinical, and commercialization activities for products it elects to advance. In other words, this is a partnership that can become a genuine burn-transfer mechanism later. It is not yet one today.

Merck: This partnership is more concrete than it first appears, but also narrower. ModeX had already received a $50.0 million upfront payment historically, remains eligible for up to $860.0 million of additional milestones, and still holds tiered royalty rights. Beyond that, the company says it has spent $26.8 million of EBV development costs to date for which Merck has provided or will provide reimbursement. Even so, the direct R&D offset fell sharply in 2025, and management explains that much of the Phase 1 work was done in 2024 and completed in 2025. The right read, then, is that Merck is a real support mechanism, but a lumpy one, tied to one program and to one development timetable.

Entera: Here the economics run almost opposite to the casual read. In March 2025, OPKO and Entera formalized the oral OXM program on a 60% 40% basis, and OPKO bought Entera shares for about $8 million so Entera could fund its 40% share through the end of Phase 1. After Phase 1, Entera has the right to keep funding its share and preserve its 40% stake, but if it does not, its interest drops to 15% and OPKO keeps 85% while taking over all ongoing funding and development responsibility. In February 2026, the partnership was expanded again into LA-PTH on a 50% 50% basis. That is a welcome expansion of optionality, but it also adds another program that requires money rather than generating money.

The Filing Itself Shows That Funding Coverage Still Lags the R&D Curve

The simplest way to test whether these partnerships already “fund the pipeline” is not to count counterparties, but to read the two most relevant lines together: total R&D expense and the grants-and-funding offset.

That is the center of the continuation thesis. The partnerships do not just bring money in. They also pull programs forward and therefore raise the execution base. BARDA funds work, but to recognize the revenue OPKO first has to perform the work. Regeneron can only take expense out of OPKO’s budget once it actually selects and advances molecules. Merck reimburses EBV activity, but that does not cover everything happening around it. Entera adds risk sharing, but it also required OPKO to send cash out the door to keep the program moving.

So the superficial read, “there are many partners, therefore the pipeline is funded,” misses the order of importance. The right question is what portion of the partnership set is hard current money against work already performed, what portion is a future offload mechanism in which an outside partner will take burn only after a development decision, and what portion actually adds another layer of capital commitment before it reduces one.

So Do the Partnerships Fund the Pipeline, or Just Push the Capital Question Outward?

On the disclosure available here, the answer is a sharp middle ground: the partnerships fund pieces of the pipeline, but they do not yet fund the pipeline as a whole. BARDA is the only source that currently looks like a visible ongoing funding framework for work already underway. Regeneron may later become a deeper funding layer, but for now it mostly provides future optionality. Merck offers real support, but for one program and on an uneven cadence. Entera improves the risk-sharing structure, yet in the near term it even consumes OPKO cash.

That is exactly why the headlines and the filing are telling two different stories. The headlines describe a platform that is attracting serious names. The filing says that platform also becomes more expensive to run as it advances. Both claims are true at the same time. Anyone reading this as a fully funded pipeline is being too generous with the current evidence. Anyone ignoring the partnerships entirely is also missing the point. The outside money is real, but it is selective, contingent, and in some cases arrives only after OPKO has already expanded the cost base.

What would have to happen for that read to change? First, BARDA would need to keep progressing without another scope cut and with a recognition pace that starts to consume the $49.9 million remaining through February 2028. Second, Regeneron would need to move from a discovery collaboration to actual molecule selection and partner-funded advancement. Third, Merck would need to show up more forcefully either in current offsets or milestone economics. And fourth, Entera would need to keep funding its share after Phase 1, otherwise OPKO ends up owning more precisely when the budget burden becomes heavier.

Until that happens, the partnerships look less like proof that the pipeline already funds itself and more like a mechanism that buys OPKO time rather than erasing the capital question.